By Maggie Fick and Stine Jacobsen
LONDON/COPENHAGEN (Reuters) -Novo Nordisk’s CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug candidate CagriSema as the company considers dosage escalation and trial length for a new study.
The company on Dec. 20 revealed results in its late-stage study which were weaker than expected, wiping about $125 billion from its market value.
Novo said at the time it would start a new trial in the first half of the year.
The drug is crucial to Novo’s search for a successor to its blockbuster weight-loss drug Wegovy that is more powerful than Eli Lilly’s rival Zepbound, also known as Mounjaro.
CEO Lars Fruergaard Jorgensen told journalists on a media call after the company released quarterly results on Wednesday that the company was confident in CagriSema’s biology and encouraged by the data.
He declined though to answer directly why only 57.3% of trial participants reached the highest dose of the medicine, a question which has puzzled the market since the December data.
Investors and analysts have speculated it could be because participants suffered harsh side-effects or they achieved good weight loss on lower doses. The company said at the time side-effects were inline with other weight-loss drugs like Wegovy.
“It’s clear when you work with a potent biology like CagriSema, you see people losing weight significantly, and some of those will hit the weight they attempted to reach and the BMI they are targeting,” Jorgensen said.
Investors and analysts were also surprised to learn in December that the trial used a “flexible” protocol, permitting patients to change their dose rather than follow a schedule.
Asked on the call whether Novo made a mistake with that protocol, Jorgensen said: “No”.
Flexibility was needed to address the risk that participants who lost significant weight over a short period would drop out of the trial because they felt they had lost enough weight, he said.
The company said on Wednesday it plans to submit CagriSema for regulatory approval during the first quarter of 2026, slightly later than its previous expectation of end-2025.
(Reporting by Maggie Fick and Stine Jacobsen, Editing by Louise Heavens and Elaine Hardcastle)
Brought to you by www.srnnews.com